Teleflex (TFX) Expected to Release Quarterly Earnings on Thursday

Key Points

• Teleflex is expected to report Q3 2026 earnings before the market opens on October 29. Analysts forecast $1.90 in earnings per share and $565.51 million in revenue, while full-year guidance is $6.90–$7.20 EPS.
• In its previous quarter, Teleflex earned $1.76 per share, beating consensus by $0.48, and generated $570.33 million in revenue, up 28.9% year over year.
• Shares opened at $130.47, below the analyst consensus target of $154.40. Analysts collectively rate the stock “Moderate Buy,” and Teleflex recently paid a quarterly dividend of $0.34 per share.

Teleflex (NYSE:TFX - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Teleflex to post earnings of $1.90 per share and revenue of $565.51 million for the quarter. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Parties may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The company had revenue of $570.33 million for the quarter, compared to analyst estimates of $559.59 million. During the same period last year, the firm earned $3.73 earnings per share. The firm's revenue was up 28.9% on a year-over-year basis. On average, analysts expect Teleflex to post $7.22 EPS for the current fiscal year and $10.89 EPS for the next fiscal year.

Teleflex Stock Down 0.5%

Teleflex stock opened at $130.47 on Thursday. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $145.00. The stock has a market cap of $5.53 billion, a PE ratio of -5.60, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83. The firm's 50-day simple moving average is $130.95 and its 200 day simple moving average is $130.62. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th were paid a $0.34 dividend. The ex-dividend date was Friday, August 14th. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex's dividend payout ratio (DPR) is -5.84%.

Wall Street Analysts Forecast Growth

TFX has been the topic of several recent analyst reports. Truist Financial dropped their target price on shares of Teleflex from $150.00 to $142.00 and set a "hold" rating on the stock in a research report on Wednesday, October 14th. Mizuho boosted their target price on Teleflex from $140.00 to $145.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Zacks Research raised Teleflex from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 24th. UBS Group increased their price target on Teleflex from $145.00 to $158.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Teleflex in a research report on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $154.40.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company's portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.